Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems (DCTH) Investor Presentation - Slideshow
01:44pm, Friday, 04'th Sep 2020
The following slide deck was published by Delcath Systems, Inc. in conjunction with this event..
Delcath Systems, Inc. (DCTH) CEO John Purpura on Q2 2020 Results - Earnings Call Transcript
10:29pm, Thursday, 13'th Aug 2020
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2020 Results Earnings Conference Call August 13, 2020, 04:30 PM ET Company Participants James Carbonara - Hayden IR John Purpura - Interim Chief Executive Office
Delcath Systems, Inc. Announces Second Quarter 2020 Results
08:01pm, Thursday, 13'th Aug 2020
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, annou
Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
08:01pm, Thursday, 06'th Aug 2020
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a
LD Micro - Announces Preliminary List of Presenters for the LD-500
01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
Delcath : to Present at Canaccord Genuity 40th Annual Growth Conference | MarketScreener
05:48pm, Monday, 03'rd Aug 2020Delcath to Present at Canaccord Genuity 40th Annual Growth Conference
05:48pm, Monday, 03'rd Aug 2020
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a
Delcath Systems (OTCMKTS:DCTH) Trading Up 16.7%
01:48am, Saturday, 18'th Jul 2020
Delcath Systems, Inc. (OTCMKTS:DCTH) shot up 16.7% during trading on Friday . The company traded as high as $10.95 and last traded at $10.78, 104,100 shares traded hands during trading. An increase of
Delcath Announces Leadership Transition
12:30pm, Tuesday, 26'th May 2020
Appoints John Purpura as interim Chief Executive Officer. NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on liver-directed treat
SINGAPORE, May 24, 2020 (PR Newswire Europe via COMTEX) --
Singapore medtech company HistoIndex [https://www.histoindex.com/]'s AI-based stain-free digital...
Encode Ideas, L.P. Announces the Initiation of Research Coverage on Delcath Systems, Inc.
12:30pm, Tuesday, 19'th May 2020
Dover, Delaware--(Newsfile Corp. - May 19, 2020) - Encode Ideas, L.P. Initiates Research on Delcath Systems, Inc (NASDAQ: DCTH). The full research publication is available here and available on our we
Delcath Announces First Quarter 2020 Results
10:30am, Friday, 15'th May 2020
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended March 3
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
08:05pm, Tuesday, 05'th May 2020
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced u
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
02:17pm, Friday, 01'st May 2020
Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22
Delcath Systems appoints Elizabeth Czerepak to board of directors DCTH
01:44pm, Wednesday, 19'th Feb 2020
Delcath Systems appoints Elizabeth Czerepak to board of directors DCTH
